RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $148 Price Target

Benzinga ·  Nov 22, 2023 01:49

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $148 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment